• M Trevisani, A Milan, R Gatti, A Zanasi, S Harrison, G Fontana, A H Morice, and P Geppetti.
• Center of Excellence for the Study of Inflammation, University of Ferrara, Ferrara, Italy. tvm@unife.it
• Thorax. 2004 Sep 1; 59 (9): 769-72.

BackgroundIodo-resiniferatoxin (I-RTX) has recently been described as an ultra potent antagonist of the transient receptor potential vanilloid-1 (TRPV1).MethodsThe ability of I-RTX to inhibit cough induced by inhalation of two putative TRPV1 stimulants (capsaicin and citric acid) was tested in non-anaesthetised guinea pigs.ResultsPretreatment with I-RTX either intraperitoneally (0.03-0.3 micromol/kg) or by aerosol (0.1-3 microM) reduced the number of coughs produced by inhalation of citric acid (0.25 M) and capsaicin (30 microM) in a dose dependent manner. Capsazepine (CPZ) also reduced citric acid and capsaicin induced cough, but the activity of I-RTX was 10-100 times more potent than CPZ in all the experimental conditions tested.ConclusionsI-RTX is a novel and potent antitussive drug which inhibits cough mediated by agents possibly acting via TRPV1 activation.

14 keywords...

hide…